The cetuximab saga.
Bottom Line(s): We won't mince words. These are lackluster outcomes following the glimmer of hope offered by initial cetuximab results. But let’s not forget the persistent truth that patients with HPV-driven oropharyngeal cancers do extremely well with our tried and true radiation with concurrent cisplatin. More globally, this should serve as yet another cautionary tale of de-escalating treatment without the due diligence of appropriate phase 3 trials. To end on a positive note, we salute the patients who volunteered for these studies and the investigators who dedicated years to their design, enrollment, and analyses. | Mehanna & Gillison, Lancet 2018